| Jersey (Channel Islands)(State or other jurisdiction of incorporation or organization)                                                 | 98-0601486(I.R.S. Employer Identification No.)                                  |
|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|  5 Riverwalk, Citywest Business Campus, Dublin 24, Republic of Ireland (Address of principal executive offices and zip code) |  +353 1 429 7700(Registrant’s telephone number, including area code) |

----

----

|                                                                                                           |                                                                                                                |  Page |
|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|------------|
|                                                                                                           |                                                                                                                |
| Explanatory Note                                                                                               | 4                                                                                                                   |
| PART I   FINANCIAL INFORMATION                                                                  |                                                                                                                |
| ITEM 1.  FINANCIAL STATEMENTS                                                                        |                                                                                                                |
|                                                                                                           | Unaudited Consolidated Balance Sheets at March 31, 2011 and December 31, 2010                                       | 5          |
|                                                                                                           | Unaudited Consolidated Statements of Income for the three months to March 31, 2011 and March 31, 2010               | 7          |
|                                                                                                           | Unaudited Consolidated Statement of Changes in Equity for the three months to March 31, 2011                        | 9          |
|                                                                                                           | Unaudited Consolidated Statements of Comprehensive Income for the three months to March 31, 2011 and March 31, 2010 | 10         |
|                                                                                                           | Unaudited Consolidated Statements of Cash Flows for the three months to March 31, 2011 and March 31, 2010           | 11         |
|                                                                                                           | Notes to the Unaudited Consolidated Financial Statements                                                            | 13         |
| ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 30                                                                                                                  |
| ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                                  | 41                                                                                                                  |
| ITEM 4.  CONTROLS AND PROCEDURES                                                                     | 41                                                                                                                  |
|                                                                                                           |                                                                                                                |
| PART II  OTHER INFORMATION                                                                           | 41                                                                                                                  |
| ITEM 1.  LEGAL PROCEEDINGS                                                                           | 41                                                                                                                  |
| ITEM 1A.  RISK FACTORS                                                                               | 41                                                                                                                  |
| ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS                                 | 41                                                                                                                  |
| ITEM 3.  DEFAULTS UPON SENIOR SECURITIES                                                             | 41                                                                                                                  |
| ITEM 4.  OTHER INFORMATION                                                                           | 41                                                                                                                  |
| ITEM 5.  EXHIBITS                                                                                    | 42                                                                                                                  |

----

----

|                                      |   |   |   |   | March 31, |      |    | December 31, |   |
|-------------------------------------------|--------|--------|--------|--------|-----------|-----------|---------|--------------|--------|
|                                      |   |   |   |   | 2011      |      |    | 2010         |   |
|                                      |   | Notes  |   |   |      | $’M |    |         |   | $’M |   |
| ASSETS                                    |   |   |   |   |      |      |    |         |   |   |   |
| Current assets:                           |   |   |   |   |      |      |    |         |   |   |   |
| Cash and cash equivalents                 |   |   |   |   |      | 712.0     |    |         |   | 550.6 |   |
| Restricted cash                           |   |   |   |   |      | 30.8      |    |         |   | 26.8 |   |
| Accounts receivable, net                  |   |   | 3      |   |      |      | 786.3   |         |   |   | 692.5 |   |
| Inventories                               |   |   | 4      |   |      |      | 281.9   |         |   |   | 260.0 |   |
| Deferred tax asset                        |   |   |   |   |      |      | 129.7   |         |   |   | 182.0 |   |
| Prepaid expenses and other current assets |   |   | 5      |   |      |      | 170.8   |         |   |   | 168.4 |   |
| Total current assets                      |   |   |   |   |      |      | 2,111.5 |         |   |   | 1,880.3 |   |
|                                      |   |   |   |   |      |      |    |         |   |   |   |   |
| Non-current assets:                       |   |   |   |   |      |      |    |         |   |   |   |   |
| Investments                               |   |   |   |   |      |      | 119.5   |         |   |   | 101.6 |   |
| Property, plant and equipment, net        |   |   |   |   |      |      | 869.8   |         |   |   | 853.4 |   |
| Goodwill                                  |   |   |   |   |      |      | 414.9   |         |   |   | 402.5 |   |
| Other intangible assets, net              |   |   | 6      |   |      |      | 1,985.8 |         |   |   | 1,978.9 |   |
| Deferred tax asset                        |   |   |   |   |      |      | 116.9   |         |   |   | 110.4 |   |
| Other non-current assets                  |   |   |   |   |      |      | 54.4    |         |   |   | 60.5 |   |
| Total assets                              |   |   |   |   |      |      | 5,672.8 |         |   |   | 5,387.6 |   |
| LIABILITIES AND EQUITY                    |   |   |   |   |      |      |    |         |   |   |   |   |
| Current liabilities:                      |   |   |   |   |      |      |    |         |   |   |   |   |
| Accounts payable and accrued expenses     |   |   | 7      |   |      |      | 1,208.5 |         |   |   | 1,239.3 |   |
| Deferred tax liability                    |   |   |   |   |      |      | 4.4     |         |   |   | 4.4 |   |
| Other current liabilities                 |   |   | 8      |   |      |      | 35.7    |         |   |   | 49.6 |   |
| Total current liabilities                 |   |   |   |   |      |      | 1,248.6 |         |   |   | 1,293.3 |   |
|                                      |   |   |   |   |      |      |    |         |   |   |   |   |
| Non-current liabilities                   |   |   |   |   |      |      |    |         |   |   |   |   |
| Convertible bonds                         |   |   |   |   |      |      | 1,100.0 |         |   |   | 1,100.0 |   |
| Deferred tax liability                    |   |   |   |   |      |      | 348.4   |         |   |   | 352.1 |   |
| Other non-current liabilities             |   |   | 9      |   |      |      | 206.7   |         |   |   | 190.8 |   |
| Total liabilities                         |   |   |   |   |      |      | 2,903.7 |         |   |   | 2,936.2 |   |
| Commitments and contingencies             |   |   | 10     |   |      |      |    |         |   |   |   |   |

----

|                                                                                                                                                                                                    |   |   | March 31, |      |   | December 31, |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-----------|-----------|--------|--------------|--------|
|                                                                                                                                                                                                    |   |   | 2011      |      |   | 2010         |   |
|                                                                                                                                                                                                    | Notes  |   |      | $’M |   |         |   | $’M |   |
| Equity:                                                                                                                                                                                                 |   |   |      |      |   |         |   |   |   |
| Common stock of 5p par value; 1,000 million shares authorized; and 562.2 million shares issued and outstanding (2010: 1,000 million shares authorized; and 562.2 million shares issued and outstanding) |   |   |      | 55.7      |   |         |   | 55.7 |   |
| Additional paid-in capital                                                                                                                                                                              |   |   |      | 2,769.6   |   |         |   | 2,746.4 |   |
| Treasury stock: 10.9 million shares (2010: 14.0 million shares)                                                                                                                                         |   |   |      | (217.3    | )      |         |   | (276.1 | ) |
| Accumulated other comprehensive income                                                                                                                                                                  |   |   |      | 168.8     |   |         |   | 85.7 |   |
| Accumulated deficit                                                                                                                                                                                     |   |   |      | (7.7      | )      |         |   | (160.3 | ) |
| Total equity                                                                                                                                                                                            |   |   |      | 2,769.1   |   |         |   | 2,451.4 |   |
| Total liabilities and equity                                                                                                                                                                            |   |   |      | 5,672.8   |   |         |   | 5,387.6 |   |

----

| 3 months to March 31,                                                                                            |   |   |   |   | 2011   |      |   | 2010   |   |
|------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|-----------|--------|--------|--------|
|                                                                                                             |   | Notes  |   |   |   | $’M |   |   |   | $’M |   |
| Revenues:                                                                                                        |   |   |   |   |   |      |   |   |   |   |   |
|   Product sales                                                                                        |   |   |   |   |   | 889.3     |   |   |   | 718.2 |   |
|   Royalties                                                                                            |   |   |   |   |   | 73.6      |   |   |   | 95.3 |   |
|   Other revenues                                                                                       |   |   |   |   |   | 9.3       |   |   |   | 2.7 |   |
| Total revenues                                                                                                   |   |   |   |   |   | 972.2     |   |   |   | 816.2 |   |
| Costs and expenses:                                                                                              |   |   |   |   |   |      |   |   |   |   |   |
|   Cost of product sales (1)                                                                            |   |   |   |   |   | 124.5     |   |   |   | 101.9 |   |
|   Research and development                                                                             |   |   |   |   |   | 177.9     |   |   |   | 131.0 |   |
|   Selling, general and administrative (1)                                                              |   |   |   |   |   | 402.9     |   |   |   | 359.9 |   |
|   Loss on sale of product rights                                                                       |   |   |   |   |   | 1.3       |   |   |   | - |   |
|   Reorganization costs                                                                                 |   |   | 2      |   |   |      | 5.5    |   |   |   | 5.0 |   |
|   Integration and acquisition costs                                                                    |   |   |   |   |   |      | (6.4   | )      |   |   | 0.6 |   |
| Total operating expenses                                                                                         |   |   |   |   |   |      | 705.7  |   |   |   | 598.4 |   |
|                                                                                                             |   |   |   |   |   |      |   |   |   |   |   |   |
| Operating income                                                                                                 |   |   |   |   |   |      | 266.5  |   |   |   | 217.8 |   |
|                                                                                                             |   |   |   |   |   |      |   |   |   |   |   |   |
| Interest income                                                                                                  |   |   |   |   |   |      | 0.6    |   |   |   | 0.4 |   |
| Interest expense                                                                                                 |   |   |   |   |   |      | (9.2   | )      |   |   | (9.0 | ) |
| Other income, net                                                                                                |   |   |   |   |   |      | 0.3    |   |   |   | 10.8 |   |
| Total other (expense)/income, net                                                                                |   |   |   |   |   |      | (8.3   | )      |   |   | 2.2 |   |
|                                                                                                             |   |   |   |   |   |      |   |   |   |   |   |   |
| Income from continuing operations before income taxes and equity in earnings/(losses) of equity method investees |   |   |   |   |   |      | 258.2  |   |   |   | 220.0 |   |
| Income taxes                                                                                                     |   |   |   |   |   |      | (48.1  | )      |   |   | (53.6 | ) |
| Equity in earnings/(losses) of equity method investees, net of taxes                                             |   |   |   |   |   |      | 1.2    |   |   |   | (0.5 | ) |
| Net income                                                                                                       |   |   |   |   |   |      | 211.3  |   |   |   | 165.9 |   |

|   | (1) | Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.4 million for the three months to March 31, 2011 (2010: $0.4 million). Selling, general and administrative costs includes amortization for intangible assets relating to intellectual property rights acquired of $36.1 million for the three months to March 31, 2011 (2010: $34.6 million). |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3 months to March 31,                         | Notes  |   | 2011   |   |   | 2010   |   |
|-----------------------------------------------|--------|--------|--------|--------|--------|--------|--------|
|                                          |   |   |   |   |   |   |   |
| Earning per ordinary share - basic            |   |   |   |   |   |   |   |
|                                          |   |   |   |   |   |   |   |
|                                          |   |   |   |   |   |   |   |
| Earnings per ordinary share - basic           |   |   |   | 38.5   | c      |   |   | 30.5 | c |
|                                          |   |   |   |   |   |   |   |   |   |
| Earnings per ordinary share - diluted         |   |   |   |   |   |   |   |   |   |
|                                          |   |   |   |   |   |   |   |   |   |
| Earnings per ordinary share - diluted         |   |   |   | 37.0   | c      |   |   | 29.7 | c |
|                                          |   |   |   |   |   |   |   |   |   |
| Weighted average number of shares (millions): |   |   |   |   |   |   |   |   |   |
| Basic                                         | 13     |   |   | 549.5  |   |   |   | 543.9 |   |
| Diluted                                       | 13     |   |   | 593.6  |   |   |   | 586.1 |   |

----

|                                                                                                       |   | Shire plc shareholders' equity |   |   |                           |   |
|------------------------------------------------------------------------------------------------------------|--------|--------------------------------|--------|--------|--------------------------------|--------|
|                                                                                                       |   | Commonstock$'M                 |   |   | CommonstockNumber of sharesM's |   |   | Additionalpaid-incapital$’M |   |   | Treasurystock$'M |   |   | Accumulated other comprehensive income$'M |   |   | Accumulated deficit$'M |   |   | Total equity$'M |   |
| As at January 1, 2011                                                                                      |   |                           | 55.7   |   |                           |   | 562.2 |   |   |   | 2,746.4 |   |   |   | (276.1 | ) |   |   | 85.7 |   |   |   | (160.3 | ) |   |   | 2,451.4 |   |
| Net income                                                                                                 |   |                           | -      |   |                           |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 211.3 |   |   |   | 211.3 |   |
| Foreign currency translation                                                                               |   |                           | -      |   |                           |   | - |   |   |   | - |   |   |   | - |   |   |   | 70.6 |   |   |   | - |   |   |   | 70.6 |   |
| Options exercised                                                                                          |   |                           | -      |   |                           |   | - |   |   |   | 0.1 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 0.1 |   |
| Share-based compensation                                                                                   |   |                           | -      |   |                           |   | - |   |   |   | 15.7 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 15.7 |   |
|                                                                                                       |   |                           |   |   |                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Excess tax benefit associated with exercise of stock options                                               |   |                           | -      |   |                           |   | - |   |   |   | 7.4 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 7.4 |   |
|                                                                                                       |   |                           |   |   |                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares released by Employee Share Ownership Trust ("ESOT")  to satisfy exercise of stock options |   |                           | -      |   |                           |   | - |   |   |   | - |   |   |   | 58.8 |   |   |   | - |   |   |   | (58.7 | ) |   |   | 0.1 |   |
|                                                                                                       |   |                           |   |   |                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Unrealized holding gain on available-for-sale securities, net of taxes                                     |   |                           | -      |   |                           |   | - |   |   |   | - |   |   |   | - |   |   |   | 10.1 |   |   |   | - |   |   |   | 10.1 |   |
|                                                                                                       |   |                           |   |   |                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other than temporary impairment of available-for-sale securities                                           |   |                           | -      |   |                           |   | - |   |   |   | - |   |   |   | - |   |   |   | 2.4 |   |   |   | - |   |   |   | 2.4 |   |
| As at March 31, 2011                                                                                       |   |                           | 55.7   |   |                           |   | 562.2 |   |   |   | 2,769.6 |   |   |   | (217.3 | ) |   |   | 168.8 |   |   |   | (7.7 | ) |   |   | 2,769.1 |   |

----

| 3 months to March 31,                                                                                   |   | 2011   |   |   | 2010   |   |
|---------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|
|                                                                                                    |   | $'M    |   |   | $'M    |   |
|                                                                                                    |   |   |   |   |   |   |
| Net income                                                                                              |   |   | 211.3  |   |   |   | 165.9 |   |
| Other comprehensive income:                                                                             |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustments                                                                |   |   | 70.6   |   |   |   | (35.1 | ) |
| Unrealized holding gain/(loss) on available-for-sale securities (net of taxes of $2.3 and $1.6 million) |   |   | 10.1   |   |   |   | (6.7 | ) |
| Other than temporary impairment of available-for-sale securities (net of taxes of $nil and $nil)        |   |   | 2.4    |   |   |   | - |   |
| Comprehensive income                                                                                    |   |   | 294.4  |   |   |   | 124.1 |   |

|                                                                   |   | March 31, |      |   | December 31, |   |
|------------------------------------------------------------------------|--------|-----------|-----------|--------|--------------|--------|
|                                                                   |   | 2011      |      |   | 2010         |   |
|                                                                   |   |      | $’M |   |         |   | $’M |   |
| Foreign currency translation adjustments                               |   |      | 156.0     |   |         |   | 85.4 |   |
| Unrealized holding gain on available-for-sale securities, net of taxes |   |      | 12.8      |   |         |   | 0.3 |   |
| Accumulated other comprehensive income                                 |   |      | 168.8     |   |         |   | 85.7 |   |

----

| 3 months to March 31,                                                               |   | 2011   |      |   | 2010   |   |
|-------------------------------------------------------------------------------------|--------|--------|-----------|--------|--------|--------|
|                                                                                |   |   | $’M |   |   |   | $’M |   |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                               |   |   |      |   |   |   |   |   |
| Net income                                                                          |   |   | 211.3     |   |   |   | 165.9 |   |
| Adjustments to reconcile net income to net cash provided by operating activities:   |   |   |      |   |   |   |   |   |
| Depreciation and amortization                                                       |   |   | 63.5      |   |   |   | 64.3 |   |
| Share based compensation                                                            |   |   | 15.7      |   |   |   | 14.1 |   |
| Gain on sale of non-current investments                                             |   |   | -         |   |   |   | (11.1 | ) |
| Other                                                                               |   |   | (5.5      | )      |   |   | 5.2 |   |
| Movement in deferred taxes                                                          |   |   | 42.2      |   |   |   | 52.2 |   |
| Equity in (earnings)/losses of equity method investees                              |   |   | (1.2      | )      |   |   | 0.5 |   |
| Changes in operating assets and liabilities:                                        |   |   |      |   |   |   |   |   |
| Increase in accounts receivable                                                     |   |   | (74.8     | )      |   |   | (10.8 | ) |
| Increase in sales deduction accrual                                                 |   |   | 31.2      |   |   |   | 64.9 |   |
| Increase in inventory                                                               |   |   | (12.7     | )      |   |   | (24.2 | ) |
| Decrease/(increase) in prepayments and other current assets                         |   |   | 1.1       |   |   |   | (18.1 | ) |
| Decrease/(increase) in other assets                                                 |   |   | 3.9       |   |   |   | (0.6 | ) |
| Decrease in accounts payable and other liabilities                                  |   |   | (72.8     | )      |   |   | (116.1 | ) |
| Net cash provided by operating activities (A)                                       |   |   | 201.9     |   |   |   | 186.2 |   |
|                                                                                |   |   |      |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                               |   |   |      |   |   |   |   |   |
| Movements in restricted cash                                                        |   |   | (4.1      | )      |   |   | 6.3 |   |
| Purchases of non-current investments                                                |   |   | (2.5      | )      |   |   | - |   |
| Purchases of property, plant and equipment                                          |   |   | (46.5     | )      |   |   | (43.6 | ) |
| Proceeds from disposal of property, plant and equipment and non-current investments |   |   | 0.1       |   |   |   | 2.1 |   |
| Returns of equity investments                                                       |   |   | 1.1       |   |   |   | - |   |
| Net cash used in investing activities (B)                                           |   |   | (51.9     | )      |   |   | (35.2 | ) |

----

| 3 months to March 31,                                                    |   | 2011   |      |   | 2010   |   |
|--------------------------------------------------------------------------|--------|--------|-----------|--------|--------|--------|
|                                                                     |   |   | $’M |   |   |   | $’M |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                    |   |   |      |   |   |   |   |   |
| Payment under building finance obligation                                |   |   | (0.2      | )      |   |   | (0.7 | ) |
| Proceeds from exercise of options                                        |   |   | 0.2       |   |   |   | 1.5 |   |
| Tax benefit of stock based compensation                                  |   |   | 9.0       |   |   |   | 4.8 |   |
| Net cash provided by financing activities(C)                             |   |   | 9.0       |   |   |   | 5.6 |   |
| Effect of foreign exchange rate changes on cash and cash equivalents (D) |   |   | 2.4       |   |   |   | 2.0 |   |
| Net increase in cash and cash equivalents (A+B+C+D)                      |   |   | 161.4     |   |   |   | 158.6 |   |
| Cash and cash equivalents at beginning of period                         |   |   | 550.6     |   |   |   | 498.9 |   |
| Cash and cash equivalents at end of period                               |   |   | 712.0     |   |   |   | 657.5 |   |

| Supplemental information associated with continuing                                                                                 |   |   |      |   |   |   |
|-------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-----------|--------|--------|--------|
| operations:                                                                                                                         |   |   |      |   |   |   |
|                                                                                                                                |   |   |      |   |   |   |
| 3 months to March 31,                                                                                                               |   | 2011   |      |   | 2010   |   |
|                                                                                                                                |   |   | $’M |   |   |   | $’M |   |
|                                                                                                                                |   |   |      |   |   |   |   |   |
| Interest paid                                                                                                                       |   |   | (0.5      | )      |   |   | (0.7 | ) |
| Income taxes paid                                                                                                                   |   |   | (6.4      | )      |   |   | (89.7 | ) |
|                                                                                                                                |   |   |      |   |   |   |   |   |
| Non cash investing and financing activities:                                                                                        |   |   |      |   |   |   |   |   |
| Equity in Vertex Pharmaceuticals, Inc. (“Vertex”) received as part consideration for disposal of non-current investment |   |   | -         |   |   |   | 9.1 |   |

----

----

----

|                             |   |              |   |   |            |   |   |          |   |   | Closing      |   |
|----------------------------------|--------|-------------------|--------|--------|-----------------|--------|--------|---------------|--------|--------|--------------|--------|
|                             |   | Opening liability |   |   | Amount          |   |   |          |   |   | liability at |   |
|                             |   | at January 1,     |   |   | charged to      |   |   |          |   |   | March 31,    |   |
|                             |   | 2011              |   |   | re-organization |   |   | Paid/Utilized |   |   | 2011         |   |
|                             |   | $'M               |   |   | $'M             |   |   | $'M           |   |   | $'M          |   |
|                             |   |              |   |   |            |   |   |          |   |   |         |   |
| Involuntary termination benefits |   |              | 10.1   |   |            |   | 2.9    |          |   |   | (2.4         | )      |   |   | 10.6 |   |
| Other reorganization costs       |   |              | 2.3    |   |            |   | 2.6    |          |   |   | (2.5         | )      |   |   | 2.4 |   |
|                             |   |              | 12.4   |   |            |   | 5.5    |          |   |   | (4.9         | )      |   |   | 13.0 |   |

|                            |   | 2011   |      |   | 2010   |   |
|---------------------------------|--------|--------|-----------|--------|--------|--------|
|                            |   |   | $’M |   |   |   | $’M |   |
| As at January 1,                |   |   | 23.4      |   |   |   | 20.8 |   |
| Provision charged to operations |   |   | 50.4      |   |   |   | 39.5 |   |
| Provision utilization           |   |   | (54.3     | )      |   |   | (40.2 | ) |
| As at March 31,                 |   |   | 19.5      |   |   |   | 20.1 |   |

----

|             |   | March 31, |      |   | December 31, |   |
|------------------|--------|-----------|-----------|--------|--------------|--------|
|             |   | 2011      |      |   | 2010         |   |
|             |   |      | $’M |   |         |   | $’M |   |
| Finished goods   |   |      | 85.6      |   |         |   | 91.9 |   |
| Work-in-progress |   |      | 133.9     |   |         |   | 113.9 |   |
| Raw materials    |   |      | 62.4      |   |         |   | 54.2 |   |
|             |   |      | 281.9     |   |         |   | 260.0 |   |

|                         |   | March 31, |      |   | December 31, |   |
|------------------------------|--------|-----------|-----------|--------|--------------|--------|
|                         |   | 2011      |      |   | 2010         |   |
|                         |   |      | $’M |   |         |   | $’M |   |
| Prepaid expenses             |   |      | 44.8      |   |         |   | 45.1 |   |
| Income tax receivable        |   |      | 44.2      |   |         |   | 42.4 |   |
| Value added taxes receivable |   |      | 20.1      |   |         |   | 21.5 |   |
| Other current assets         |   |      | 61.7      |   |         |   | 59.4 |   |
|                         |   |      | 170.8     |   |         |   | 168.4 |   |

|                                                                                   |   | March 31, |     |   | December 31, |   |
|----------------------------------------------------------------------------------------|--------|-----------|----------|--------|--------------|--------|
|                                                                                   |   | 2011      |     |   | 2010         |   |
|                                                                                   |   |      | ’M |   |         |   | ’M |   |
| Amortized intangible assets                                                            |   |      |     |   |         |   |   |   |
| Intellectual property rights acquired for currently marketed products                  |   |      | 2,555.3  |   |         |   | 2,516.4 |   |
| Other intangible assets                                                                |   |      | 22.5     |   |         |   | 22.0 |   |
|                                                                                   |   |      | 2,577.8  |   |         |   | 2,538.4 |   |
| Unamortized intangible assets                                                          |   |      |     |   |         |   |   |   |
| Intellectual property rights acquired for In-process R&D (“IPR&D”) |   |      | 147.3    |   |         |   | 139.7 |   |
|                                                                                   |   |      | 2,725.1  |   |         |   | 2,678.1 |   |
|                                                                                   |   |      |     |   |         |   |   |   |
| Less: Accumulated amortization                                                         |   |      | (739.3   | )      |         |   | (699.2 | ) |
|                                                                                   |   |      | 1,985.8  |   |         |   | 1,978.9 |   |

----

|                         |   | Other intangible assets |      |
|------------------------------|--------|-------------------------|-----------|
|                         |   | 2011                    |      |   | 2010 |   |
|                         |   |                    | $’M |   |   |   | $’M |   |
| As at January 1,             |   |                    | 1,978.9   |   |   |   | 1,790.7 |   |
| Acquisitions                 |   |                    | -         |   |   |   | 2.7 |   |
| Amortization charged         |   |                    | (36.1     | ) |   |   | (35.0 | ) |
| Foreign currency translation |   |                    | 43.0      |   |   |   | (28.8 | ) |
| As at March 31,              |   |                    | 1,985.8   |   |   |   | 1,729.6 |   |

|                                               |   | March 31, |      |   | December 31, |   |
|----------------------------------------------------|--------|-----------|-----------|--------|--------------|--------|
|                                               |   | 2011      |      |   | 2010         |   |
|                                               |   |      | $’M |   |         |   | $’M |   |
| Trade accounts payable and accrued purchases       |   |      | 183.0     |   |         |   | 234.7 |   |
| Accrued rebates – Medicaid                   |   |      | 394.8     |   |         |   | 379.6 |   |
| Accrued rebates – Managed care               |   |      | 191.6     |   |         |   | 170.3 |   |
| Sales return reserve                               |   |      | 69.8      |   |         |   | 69.8 |   |
| Accrued bonuses                                    |   |      | 40.9      |   |         |   | 91.6 |   |
| Accrued employee compensation and benefits payable |   |      | 63.5      |   |         |   | 48.1 |   |
| R&D accruals                                   |   |      | 58.2      |   |         |   | 60.7 |   |
| Marketing accruals                                 |   |      | 29.8      |   |         |   | 26.5 |   |
| Deferred revenue                                   |   |      | 5.3       |   |         |   | 13.7 |   |
| Other accrued expenses                             |   |      | 171.6     |   |         |   | 144.3 |   |
|                                               |   |      | 1,208.5   |   |         |   | 1,239.3 |   |

----

|                      |   | March 31, |      |   | December 31, |   |
|---------------------------|--------|-----------|-----------|--------|--------------|--------|
|                      |   | 2011      |      |   | 2010         |   |
|                      |   |      | $’M |   |         |   | $’M |   |
| Income taxes payable      |   |      | 5.9       |   |         |   | 16.2 |   |
| Value added taxes         |   |      | 12.1      |   |         |   | 9.9 |   |
| Other current liabilities |   |      | 17.7      |   |         |   | 23.5 |   |
|                      |   |      | 35.7      |   |         |   | 49.6 |   |

|                          |   | March 31, |      |   | December 31, |   |
|-------------------------------|--------|-----------|-----------|--------|--------------|--------|
|                          |   | 2011      |      |   | 2010         |   |
|                          |   |      | $’M |   |         |   | $’M |   |
| Income taxes payable          |   |      | 141.7     |   |         |   | 130.0 |   |
| Deferred revenue              |   |      | 13.7      |   |         |   | 14.1 |   |
| Deferred rent                 |   |      | 12.3      |   |         |   | 12.8 |   |
| Insurance provisions          |   |      | 16.8      |   |         |   | 13.5 |   |
| Other non-current liabilities |   |      | 22.2      |   |         |   | 20.4 |   |
|                          |   |      | 206.7     |   |         |   | 190.8 |   |

|       |    |   | Operating |      |
|------------|---------|--------|-----------|-----------|
|       |    |   | leases    |      |
|       |    |   |      | $’M |   |
| 2011  |    |   |      | 25.2      |   |
| 2012  |    |   |      | 23.0      |   |
| 2013  |    |   |      | 19.4      |   |
| 2014  |    |   |      | 18.3      |   |
| 2015  |    |   |      | 15.6      |   |
| 2016  |    |   |      | 14.1      |   |
| Thereafter | 1  |   |      | 22.7      |   |
|       |    |   |      | 138.3     |   |

----

----

----

----

----

----

|        |                                      | Fair value |      |      | Fair value |         |
|-------------|-------------------------------------------|------------|-----------|-----------|------------|--------------|
|        |                                      |       | March 31, |      |       | December 31, |   |
|        |                                      |       | 2011      |      |       | 2010         |   |
|        |                                      |       |      | $’M |       |         |   | $’M |   |
| Assets      | Prepaid expenses and other current assets |       |      | -         |       |         |   | 3.7 |   |
| Liabilities | Other current liabilities                 |       |      | 3.4       |       |         |   | 2.7 |   |

|                       | Location of net (loss)/gain recognized in income |   | Amount of net (loss)/gainrecognized in income |      |
|----------------------------|--------------------------------------------------|--------|-----------------------------------------------|-----------|
| three months to            |                                             |   | March 31,                                     |      |   | March 31, |   |
|                       |                                             |   | 2011                                          |      |   | 2010 |   |
|                       |                                             |   |                                          | $’M |   |   |   | $’M |   |
| Foreign exchange contracts | Other income, net                                |   |                                          | (1.2      | ) |   |   | 18.2 |   |

|                                    |   | Carrying |   |   | Fair value |   |
|-----------------------------------------|--------|----------|--------|--------|------------|--------|
|                                    |   | value    |   |   |       |   |   |   |   |   |   |   |   |   |   |
|                                    |   |     |   |   | Total      |   |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |
| At March 31, 2011                       |   | $'M      |   |   | $'M        |   |   | $'M |   |   | $'M |   |   | $'M |   |
| Financial assets:                       |   |     |   |   |       |   |   |   |   |   |   |   |   |   |   |
| Available-for-sale securities(1)        |   |     | 98.8   |   |       |   | 98.8 |   |   |   | 98.8 |   |   |   | - |   |   |   | - |   |
| Contingent consideration receivable (2) |   |     | 58.0   |   |       |   | 58.0 |   |   |   | - |   |   |   | - |   |   |   | 58.0 |   |
|                                    |   |     |   |   |       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Financial liabilities:                  |   |     |   |   |       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign exchange contracts              |   |     | 3.4    |   |       |   | 3.4 |   |   |   | - |   |   |   | 3.4 |   |   |   | - |   |

----

|                                    |   |   |   |   | Total  |   |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |
|-----------------------------------------|--------|--------|--------|--------|--------|--------|--------|---------|--------|--------|---------|--------|--------|---------|--------|
| At December 31, 2010                    |   | $'M    |   |   | $'M    |   |   | $'M     |   |   | $'M     |   |   | $'M     |   |
| Financial assets:                       |   |   |   |   |   |   |   |    |   |   |    |   |   |    |   |
| Available-for-sale securities(1)        |   |   | 83.9   |   |   |   | 83.9   |    |   |   | 83.9    |   |   |    | -      |   |   |   | - |   |
| Contingent consideration receivable (2) |   |   | 61.0   |   |   |   | 61.0   |    |   |   | -       |   |   |    | -      |   |   |   | 61.0 |   |
| Foreign exchange contracts              |   |   | 3.7    |   |   |   | 3.7    |    |   |   | -       |   |   |    | 3.7    |   |   |   | - |   |
|                                    |   |   |   |   |   |   |   |    |   |   |    |   |   |    |   |   |   |   |   |   |
| Financial liabilities:                  |   |   |   |   |   |   |   |    |   |   |    |   |   |    |   |   |   |   |   |   |
| Foreign exchange contracts              |   |   | 2.7    |   |   |   | 2.7    |    |   |   | -       |   |   |    | 2.7    |   |   |   | - |   |

| (2) | Contingent consideration receivable is included within Prepaid expenses and other current assets and Other non-current assets in the consolidated balance sheet. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Available-for-sale securities – the fair values of available-for-sale securities are estimated based on quoted market prices for those investments. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Contingent consideration receivable – the fair value of the contingent consideration receivable has been estimated using the income approach (using a discounted cash flow method). This discounted cash flow approach uses significant unobservable inputs, such as future sales of the divested product, relevant contractual royalty rates, an appropriate discount rate and assumed weightings applied to scenarios used in deriving a probability weighted fair value. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Foreign exchange contracts – the fair values of the swap and forward foreign exchange contracts have been determined using an income approach based on current market expectations about the future cash flows. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                  |   | Contingent consideration receivable |   |
|---------------------------------------------------------------------------------------|--------|-------------------------------------|--------|
|                                                                                  |   | 2011                                |   |
|                                                                                  |   | $'M                                 |   |
|                                                                                  |   |                                |   |
| Balance at January 1,                                                                 |   |                                | 61.0   |   |
| Loss recognized in the income statement due to change in fair value during the period |   |                                | (1.3   | ) |
| Reclassification of amounts due from Noven to Other current assets                    |   |                                | (5.1   | ) |
| Foreign exchange translation recorded to other comprehensive income                   |   |                                | 3.4    |   |
|                                                                                  |   |                                |   |   |
| Balance at March 31,                                                                  |   |                                | 58.0   |   |

----

|                          |   | March 31, 2011 |      |   | December 31, 2010 |   |
|-------------------------------|--------|----------------|-----------|--------|-------------------|--------|
|                          |   | Carrying       |      |   |              |   |   | Carrying |   |   |   |   |
|                          |   | amount         |      |   | Fair value        |   |   | amount |   |   | Fair value |   |
|                          |   |           | $’M |   |              |   | $’M |   |   |   | $’M |   |   |   | $’M |   |
|                          |   |           |      |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Financial liabilities:        |   |           |      |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Convertible bonds             |   |           | 1,100.0   |   |              |   | 1,247.3 |   |   |   | 1,100.0 |   |   |   | 1,139.8 |   |
| Building financing obligation |   |           | 8.4       |   |              |   | 9.4 |   |   |   | 8.4 |   |   |   | 8.2 |   |

|   | · | Convertible bonds – the fair value of Shire’s $1,100 million 2.75% convertible bonds due 2014 is determined by reference to the market price of the instrument as the convertible bonds are publicly traded. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Building finance obligations - the fair value of building finance obligations are estimated based on the present value of future cash flows, and an estimate of the residual value of the underlying property at the end of the lease term, associated with these obligations. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3 months to March 31,                          |   | 2011     |      |   | 2010     |   |
|------------------------------------------------|--------|----------|-----------|--------|----------|--------|
|                                           |   |     | $’M |   |     |   | $’M |   |
| Amounts attributable to Shire plc shareholders |   |     |      |   |     |   |   |   |
| Numerator for basic earnings per share         |   |     | 211.3     |   |     |   | 165.9 |   |
| Interest on convertible bonds, net of tax      |   |     | 8.4       |   |     |   | 8.4 |   |
| Numerator for diluted earnings per share       |   |     | 219.7     |   |     |   | 174.3 |   |
|                                           |   |     |      |   |     |   |   |   |
|                                           |   |     |      |   |     |   |   |   |
| Weighted average number of shares:             |   |     |      |   |     |   |   |   |
|                                      |   | Millions |      |   | Millions |   |
| Basic(1)                                       |   |     | 549.5     |   |     |   | 543.9 |   |
| Effect of dilutive shares:                     |   |     |      |   |     |   |   |   |
| Share based awards to employees(2)             |   |     | 10.9      |   |     |   | 9.0 |   |
| Convertible bonds 2.75% due 2014(3)            |   |     | 33.2      |   |     |   | 33.2 |   |
| Diluted                                        |   |     | 593.6     |   |     |   | 586.1 |   |

|                          |   | 2011 (1) |   |   | 2010 (1) |   |
|-------------------------------|--------|---------------|--------|--------|---------------|--------|
|                          |   | No. of shares |   |   | No. of shares |   |
|                          |   | Millions      |   |   | Millions      |   |
| Share awards out of the money |   |          | 7.5    |   |          |   | 16.1 |   |

----

|                                        |   | SP     |      |   | HGT    |   |      | All Other |   |   | Total     |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|-----------|-----------|--------|--------|-----------|--------|
| 3 months to March 31, 2011                  |   |   | $’M |   |   |   | $’M |      |   |   | $’M |   |   |   | $’M |   |
| Product sales                               |   |   | 616.1     |   |   |   | 273.2     |      |   |   | -         |   |   |   | 889.3 |   |
| Royalties                                   |   |   | 37.5      |   |   |   | -         |      |   |   | 36.1      |   |   |   | 73.6 |   |
| Other revenues                              |   |   | 7.6       |   |   |   | 0.4       |      |   |   | 1.3       |   |   |   | 9.3 |   |
| Total revenues                              |   |   | 661.2     |   |   |   | 273.6     |      |   |   | 37.4      |   |   |   | 972.2 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Cost of product sales(1)                    |   |   | 81.8      |   |   |   | 42.7      |      |   |   | -         |   |   |   | 124.5 |   |
| Research and development(1)                 |   |   | 102.7     |   |   |   | 75.2      |      |   |   | -         |   |   |   | 177.9 |   |
| Selling, general and administrative(1)      |   |   | 266.6     |   |   |   | 80.1      |      |   |   | 56.2      |   |   |   | 402.9 |   |
| Loss on sale of product rights              |   |   | 1.3       |   |   |   | -         |      |   |   | -         |   |   |   | 1.3 |   |
| Reorganization costs                        |   |   | 2.3       |   |   |   | -         |      |   |   | 3.2       |   |   |   | 5.5 |   |
| Integration and acquisition costs           |   |   | (6.4      | )      |   |   | -         |      |   |   | -         |   |   |   | (6.4 | ) |
| Total operating expenses                    |   |   | 448.3     |   |   |   | 198.0     |      |   |   | 59.4      |   |   |   | 705.7 |   |
| Operating income/(loss)                     |   |   | 212.9     |   |   |   | 75.6      |      |   |   | (22.0     | )      |   |   | 266.5 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Total assets                                |   |   | 2,548.0   |   |   |   | 1,836.7   |      |   |   | 1,288.1   |   |   |   | 5,672.8 |   |
| Long-lived assets(2)                        |   |   | 150.2     |   |   |   | 678.8     |      |   |   | 44.7      |   |   |   | 873.7 |   |
| Capital expenditure on long-lived assets(2) |   |   | 4.8       |   |   |   | 36.3      |      |   |   | 2.8       |   |   |   | 43.9 |   |

| (1) | Depreciation from manufacturing plants ($7.7 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($4.7 million) is included in Research and development; and all other depreciation and amortization ($50.7 million) is included in Selling, general and administrative. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments). |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                        |   | SP     |      |   | HGT    |   |      | All Other |   |   | Total     |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|-----------|-----------|--------|--------|-----------|--------|
| 3 months to March 31, 2010                  |   |   | $’M |   |   |   | $’M |      |   |   | $’M |   |   |   | $’M |   |
| Product sales                               |   |   | 541.4     |   |   |   | 176.8     |      |   |   | -         |   |   |   | 718.2 |   |
| Royalties                                   |   |   | 58.6      |   |   |   | -         |      |   |   | 36.7      |   |   |   | 95.3 |   |
| Other revenues                              |   |   | 0.7       |   |   |   | 0.7       |      |   |   | 1.3       |   |   |   | 2.7 |   |
| Total revenues                              |   |   | 600.7     |   |   |   | 177.5     |      |   |   | 38.0      |   |   |   | 816.2 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Cost of product sales(1)                    |   |   | 80.4      |   |   |   | 21.5      |      |   |   | -         |   |   |   | 101.9 |   |
| Research and development(1)                 |   |   | 73.9      |   |   |   | 57.1      |      |   |   | -         |   |   |   | 131.0 |   |
| Selling, general and administrative(1)      |   |   | 249.5     |   |   |   | 62.7      |      |   |   | 47.7      |   |   |   | 359.9 |   |
| Reorganization costs                        |   |   | 3.4       |   |   |   | -         |      |   |   | 1.6       |   |   |   | 5.0 |   |
| Integration and acquisition costs           |   |   | 0.6       |   |   |   | -         |      |   |   | -         |   |   |   | 0.6 |   |
| Total operating expenses                    |   |   | 407.8     |   |   |   | 141.3     |      |   |   | 49.3      |   |   |   | 598.4 |   |
| Operating income/(loss)                     |   |   | 192.9     |   |   |   | 36.2      |      |   |   | (11.3     | )      |   |   | 217.8 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Total assets                                |   |   | 1,997.6   |   |   |   | 1,613.1   |      |   |   | 1,128.0   |   |   |   | 4,738.7 |   |
| Long-lived assets(2)                        |   |   | 184.6     |   |   |   | 436.2     |      |   |   | 53.7      |   |   |   | 674.5 |   |
| Capital expenditure on long-lived assets(2) |   |   | 2.3       |   |   |   | 25.5      |      |   |   | 1.9       |   |   |   | 29.7 |   |

| (1) | Depreciation from manufacturing plants ($8.6 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($3.7 million) is included in Research and development; and all other depreciation and amortization ($50.9 million) is included in Selling, general and administrative. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments). |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| · | On April 18, 2011 Shire launched VENVANSE for the treatment of ADHD in children in Brazil, the first launch of lisdexsamfetamine dimesylate (marketed as VYVANSE in the US) outside of North America. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | On February 10, 2011 Health Canada granted approval of LIALDA for the maintenance of remission of ulcerative colitis. |
|--------|-----------------------------------------------------------------------------------------------------------------------|

| · | On February 28, 2011 Shire announced that the US Food and Drug Administration (“FDA”) had approved the use of once-daily INTUNIV extended-release tablets as adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents aged 6 to 17 as part of a total treatment program. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | REPLAGAL remains the global market leader for the treatment of Fabry disease. Shire expects to have manufacturing capacity to continue uninterrupted treatment for all patients currently on REPLAGAL and to continue to meet anticipated demand from new and switch patients in 2011. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | In April 2011, Shire filed for approval in Europe of the new manufacturing facility in Lexington, MA for the production of REPLAGAL. Approval will allow greater manufacturing flexibility. Shire has already cleared an important milestone with the successful inspection of the facility by European authorities in support of this submission. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Shire has seen rapid adoption of VPRIV worldwide, with market share of 34% in the US and 18% globally, and patients continue to initiate treatment. Approval of the new manufacturing facility in Lexington for VPRIV will provide substantial additional capacity; process validation runs are currently ongoing. Shire’s continuing priority is to ensure long-term, uninterrupted treatment for patients on VPRIV. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | On March 3, 2011 Shire announced that the European Commission had approved FIRAZYR for self-administrated subcutaneous injections. FIRAZYR is the first and only treatment for acute Type I and Type II HAE attacks licensed for self-administration in Europe. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | On March 21, 2011 Shire announced that the FDA had assigned a Prescription Drug User Fee Act date of August 25, 2011 for the review of the New Drug Application (“NDA”) for FIRAZYR. This followed Shire’s submission of a complete response to the not approvable letter issued by the FDA regarding the NDA for FIRAZYR submitted by Jerini A.G. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Data from a recently completed Phase 2 proof-of-concept clinical trial indicates a statistically significant improvement in negative symptoms of schizophrenia. In this 14-week, flexible dose, multi-center study with open-label and double-blind components, VYVANSE was administered as adjunctive therapy to clinically stable patients with predominant negative symptom schizophrenia and taking established maintenance doses of atypical antipsychotic medications, using an open-label, rater-blinded design. VYVANSE was well tolerated, and not associated with notable worsening of positive symptoms, or new vital sign, laboratory or ECG findings. No rebound or negative or withdrawal symptoms were found in the subsequent placebo-controlled, double-blind withdrawal portion of the study. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| · | A Phase 3 clinical program has been initiated to assess the safety and efficacy of RESOLOR in the treatment of opioid-induced constipation in patients with chronic, non-cancer pain. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | In February 2011, Shire was notified by Watson Laboratories that it had submitted an Abbreviated New Drug Application (“ANDA”) under the Hatch-Waxman Act seeking permission to market a generic version of all approved strengths of ADDERALL XR. This new ANDA is not covered under the existing settlement agreements entered into in November 2007 between Shire and Watson Pharmaceuticals, Inc. (the “Settlement Agreements”). The Settlement Agreements cover a different ANDA and do not provide any license for Watson Laboratories to sell the products covered in Watson Laboratories’ new ANDA. On April 5, 2011 Shire filed a lawsuit in the US District Court for the Southern District of New York against Watson and its subsidiaries for infringement of certain of Shire’s ADDERALL XR patents and also for breach of contract in connection with the Settlement Agreements. The filing of the lawsuit triggered a stay of approval of this ANDA for up to 30 months. No trial date has been set. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | · | Product sales were up 24% to $889 million (2010: $718 million), driven by growth from VYVANSE (up 31% to $202 million), LIALDA/MEZAVANT (up 37% to $87 million), REPLAGAL (up 55% to $105 million) and VPRIV (up $53 million to $59 million). On a Non-GAAP CER basis, product sales were up 24%. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Total revenues were up 19% (Non-GAAP CER: up 19%) to $972 million (2010: $816 million). Increased product sales were partially offset by lower royalties (down 23% to $74 million), due to lower royalty income from Impax Laboratories Inc’s (“Impax”) authorized generic version of ADDERALL XR (down 59% to $17 million), as the first quarter of 2010 included royalties on launch shipments not repeated in 2011. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Operating income was up 22% to $267 million (2010: $218 million). Higher total revenues offset increased operating expenses as the Company increased investment in its R&D programs to sustain the progression of its pipeline. In the first quarter, we have increased SG&A expenditure to support our ongoing international expansion and anticipated future growth, and we also absorbed a full quarter’s operating costs for Movetis and our commercial hub in Switzerland. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Diluted earnings per ordinary share increased by 25% to 37.0c (2010: 29.7c), principally due to higher operating income and a lower effective rate of tax. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|           |   | 3 months to |   |   | 3 months to |   |   |   |   |
|----------------|--------|-------------|--------|--------|-------------|--------|--------|--------|--------|
|           |   | March 31,   |   |   | March 31,   |   |   |   |   |
|           |   | 2011        |   |   | 2010        |   |   | change |   |
|           |   | $'M         |   |   | $'M         |   |   | %      |   |
| Product sales  |   |        | 889.3  |   |        |   | 718.2  |   |   |   | +24 |   |
| Royalties      |   |        | 73.6   |   |        |   | 95.3   |   |   |   | -23 |   |
| Other revenues |   |        | 9.3    |   |        |   | 2.7    |   |   |   | +244 |   |
| Total          |   |        | 972.2  |   |        |   | 816.2  |   |   |   | +19 |   |

----

|                |   | 3 months to |   |   | 3 months to |   |   |          |   |   |         |   |   |            |   |   |        |   |
|---------------------|--------|-------------|--------|--------|-------------|--------|--------|---------------|--------|--------|--------------|--------|--------|-----------------|--------|--------|-------------|--------|
|                |   | March 31,   |   |   | March 31,   |   |   | Product sales |   |   | Non-GAAP CER |   |   | US prescription |   |   | Exit market |   |
|                |   | 2011        |   |   | 2010        |   |   | growth        |   |   | growth       |   |   | growth1         |   |   | share1      |   |
|                |   | $'M         |   |   | $'M         |   |   | %             |   |   | %            |   |   | %               |   |   | %           |   |
| SP                  |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |
| ADHD                |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |
| VYVANSE             |   |        | 202.3  |   |        |   | 154.4  |          |   |   | +31          |   |   |            | +31    |   |        |   | +24 |   |   |   | 15 |   |
| ADDERALL XR         |   |        | 111.2  |   |        |   | 91.8   |          |   |   | +21          |   |   |            | +21    |   |        |   | +12 |   |   |   | 8 |   |
| INTUNIV             |   |        | 41.9   |   |        |   | 34.5   |          |   |   | +21          |   |   |            | +21    |   |        |   | +152 |   |   |   | 3 |   |
| EQUASYM             |   |        | 4.6    |   |        |   | 2.4    |          |   |   | +92          |   |   |            | +90    |   |        |   | n/a |   |   |   | n/a | 2  |
| DAYTRANA            |   |        | -      |   |        |   | 18.4   |          |   |   | n/a          |   |   |            | n/a    |   |        |   | n/a |   |   |   | n/a |   |
|                |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| GI                  |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| LIALDA / MEZAVANT   |   |        | 87.1   |   |        |   | 63.6   |          |   |   | +37          |   |   |            | +37    |   |        |   | +13 |   |   |   | 20 |   |
| PENTASA             |   |        | 64.5   |   |        |   | 58.2   |          |   |   | +11          |   |   |            | +11    |   |        |   | - |   |   |   | 15 |   |
| RESOLOR             |   |        | 0.9    |   |        |   | -      |          |   |   | n/a          |   |   |            | n/a    |   |        |   | n/a | 3  |   |   | n/a | 3  |
|                |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| General Products    |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| FOSRENOL            |   |        | 41.2   |   |        |   | 47.1   |          |   |   | -13          |   |   |            | -13    |   |        |   | -14 |   |   |   | 6 |   |
| XAGRID              |   |        | 22.7   |   |        |   | 23.3   |          |   |   | -3           |   |   |            | -3     |   |        |   | n/a |   |   |   | n/a | 2  |
| CARBATROL           |   |        | 16.6   |   |        |   | 20.1   |          |   |   | -17          |   |   |            | -17    |   |        |   | -7 |   |   |   | 59 |   |
| Other product sales |   |        | 23.1   |   |        |   | 27.6   |          |   |   | -16          |   |   |            | -18    |   |        |   | n/a |   |   |   | n/a |   |
|                |   |        | 616.1  |   |        |   | 541.4  |          |   |   | +14          |   |   |            |   |   |        |   |   |   |   |   |   |   |
| HGT                 |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| REPLAGAL            |   |        | 105.4  |   |        |   | 68.0   |          |   |   | +55          |   |   |            | +56    |   |        |   | n/a | 3  |   |   | n/a | 3  |
| ELAPRASE            |   |        | 103.5  |   |        |   | 100.8  |          |   |   | +3           |   |   |            | +2     |   |        |   | n/a | 2  |   |   | n/a | 2  |
| VPRIV               |   |        | 59.0   |   |        |   | 5.8    |          |   |   | +917         |   |   |            | +921   |   |        |   | n/a |   |   |   | n/a | 2  |
| FIRAZYR             |   |        | 5.3    |   |        |   | 2.2    |          |   |   | +141         |   |   |            | +141   |   |        |   | n/a | 3  |   |   | n/a | 3  |
|                |   |        | 273.2  |   |        |   | 176.8  |          |   |   | +55          |   |   |            |   |   |        |   |   |   |   |   |   |   |
| Total product sales |   |        | 889.3  |   |        |   | 718.2  |          |   |   | +24          |   |   |            |   |   |        |   |   |   |   |   |   |   |

| (1) | Data provided by IMS Health National Prescription Audit (“IMS NPA”). Exit market share represents the average monthly US market share in the month ended March 31, 2011. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | IMS NPA Data not available. |
|-----|-----------------------------|

| (3) | Not sold in the US in Q1 2011. |
|-----|--------------------------------|

----

----

|           |   | 3 months to |   |   | 3 months to |   |   |   |   |
|----------------|--------|-------------|--------|--------|-------------|--------|--------|--------|--------|
|           |   | March 31,   |   |   | March 31,   |   |   |   |   |
|           |   | 2011        |   |   | 2010        |   |   | Change |   |
|           |   | $'M         |   |   | $'M         |   |   | %      |   |
| 3TC and ZEFFIX |   |        | 35.5   |   |        |   | 36.6   |   |   |   | -3 |   |
| ADDERALL XR    |   |        | 16.8   |   |        |   | 40.8   |   |   |   | -59 |   |
| Others         |   |        | 21.3   |   |        |   | 17.9   |   |   |   | +19 |   |
| Total          |   |        | 73.6   |   |        |   | 95.3   |   |   |   | -23 |   |

----

----

|                          |   | March 31, |      |   | December 31, |   |
|-------------------------------|--------|-----------|-----------|--------|--------------|--------|
|                          |   | 2011      |      |   | 2010         |   |
|                          |   |      | $’M |   |         |   | $’M |   |
| Cash and cash equivalents     |   |      | 712.0     |   |         |   | 550.6 |   |
| Convertible debt              |   |      | 1,100.0   |   |         |   | 1,100.0 |   |
| Building financing obligation |   |      | 8.3       |   |         |   | 8.4 |   |
| Total debt                    |   |      | 1,108.3   |   |         |   | 1,108.4 |   |
| Net debt                      |   |      | (396.3    | )      |         |   | (557.8 | ) |

----

----

----

| 2.01 | Agreement and Plan of Merger by and among Shire Pharmaceuticals Group plc, Transkaryotic Therapies, Inc. and Sparta Acquisition Corporation, dated as of April 21, 2005.(1) |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.02 | Agreement of Merger dated as of February 20, 2007 among Shire plc, Shuttle Corporation and New River Pharmaceuticals, Inc.(2) |
|------|-------------------------------------------------------------------------------------------------------------------------------|

| 2.03 | Business Combination Agreement dated as of July 3, 2008 between Maia Elfte Vermögensverwaltungs GmbH and Jerini AG.(3) |
|------|-----------------------------------------------------------------------------------------------------------------------------|

| 2.04 | Heads of Agreement by and among Shire plc and Movetis NV relating to a friendly tender offer, dated August 3, 2010. |
|------|---------------------------------------------------------------------------------------------------------------------|

| 3.01 | Form of Memorandum of Association of Shire plc as adopted by a special resolution passed on April 10, 2008 and amended by a special resolution passed on September 24, 2008.(4) |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.02 | Form of Articles of Association of Shire plc as amended by a special resolution passed on April 26, 2011 and adopted by a special resolution passed on April 26, 2011.(5) |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.01 | Form of Assignment and Novation Agreement between Shire Limited, Shire plc, JPMorgan Chase Bank, N.A. dated April 16, 2008 relating to the Deposit Agreement among Shire plc, JPMorgan Chase Bank, N.A. as depositary and all holders from time to time of ADRs issued thereunder dated November 21, 2005.(6) |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.02 | Form of Deposit Agreement among Shire plc, JPMorgan Chase Bank, N.A. as depositary and all holders from time to time of ADRs issued thereunder dated November 21, 2005.(7) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.03 | Form of Ordinary Share Certificate of Shire Limited.(8) |
|------|---------------------------------------------------------|

| 4.04 | Form of American Depositary Receipt Certificate of Shire Limited.(9) |
|------|----------------------------------------------------------------------|

| 4.05 | Trust Deed for the New Shire Income Access Trust, dated August 29, 2008.(10) |
|------|------------------------------------------------------------------------------|

| 10.01 | Tender and Support Agreement dated as of February 20, 2007 among Shire plc, Mr. Randal J. Kirk and the other parties named therein. (11) |
|-------|------------------------------------------------------------------------------------------------------------------------------------------|

| 10.02 | Multicurrency Term and Revolving Facilities Agreement as of February 20, 2007 by and among Shire plc, ABN AMRO Bank N.V., Barclays Capital, Citigroup Global Markets Limited, The Royal Bank of Scotland plc, and Barclays Bank plc.(12) |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.03 | Accession and Amendment Deed dated April 15, 2008 between Shire Limited, Shire plc, certain subsidiaries of Shire plc and Barclays Bank PLC as Facility Agent relating to a US $1,200,000,000 facility agreement dated February 20, 2007 (as amended by a syndication and amendment agreement dated July 19, 2007).(13) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.04 | Subscription Agreement dated May 2, 2007 relating to the 2.75% Convertible Bonds due 2014 between Shire plc and ABN AMRO Bank N.V. and NM Rothschild & Sons Limited (trading together as ABN AMRO Rothschild, an unincorporated equity capital markets joint venture) and Barclays Bank PLC and Citigroup Global Markets Limited and Goldman Sachs International and Morgan Stanley & Co. International plc and others.(14) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.05 | Amending Subscription Agreement dated May 8, 2007 relating to the 2.75% Convertible Bonds due 2014 between Shire plc and ABN AMRO Bank N.V. and NM Rothschild & Sons Limited (trading together as ABN AMRO Rothschild, an unincorporated equity capital markets joint venture) and Barclays Bank PLC and Citigroup Global Markets Limited and Goldman Sachs International and Morgan Stanley & Co. International plc and others.(15) |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.06 | Trust Deed dated May 9, 2007 relating to the 2.75% Convertible Bonds due 2014 between Shire plc and BNY Corporate Trustee Services Limited.(16) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.07 | Supplemental Trust Deed dated April 15, 2008 between Shire Limited, Shire plc and BNY Corporate Trustee Services Limited relating to a trust deed dated May 9, 2007 relating to US $1,100,000,000 2.75% Convertible Bonds due 2014.(17) |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.08 | Accession and Amendment Agreement dated April 15, 2008 between Shire Limited, Shire plc, BNY Corporate Trustee Services Limited and The Bank of New York relating to a paying and conversion agency agreement dated May 9, 2007 relating to US $1,100,000,000 2.75% Convertible Bonds due 2014.(18) |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.09* | Revised and Restated Master License Agreement dated November 20, 1995 among Shire BioChem Inc (f/k/a BioChem Pharma Inc.), Glaxo Group Limited, Glaxo Wellcome Inc. (formerly Glaxo Canada Inc.), Glaxo Wellcome Inc. (formerly Glaxo Inc.), Tanaud Holdings (Barbados) Limited, Tanaud International B.V. and Tanaud LLC.(19) |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.10* | Settlement Agreement, dated August 14, 2006 by and between Shire Laboratories Inc. and Barr.(20) |
|--------|--------------------------------------------------------------------------------------------------|

| 10.11* | Product Development and License Agreement, dated August 14, 2006 by and between Shire LLC and Duramed Pharmaceuticals, Inc.(21) |
|--------|---------------------------------------------------------------------------------------------------------------------------------|

| 10.12* | Product Acquisition and License Agreement, dated August 14, 2006 by and among Shire LLC, Shire plc and Duramed Pharmaceuticals, Inc.(22) |
|--------|------------------------------------------------------------------------------------------------------------------------------------------|

| 10.13 | Service Agreement between Shire plc and Mr Angus Russell, dated March 10, 2004.(23) |
|-------|-------------------------------------------------------------------------------------|

| 10.14 | Novation Agreement dated November 21, 2005 relating to the Employment Agreement of Angus Russell dated March 10, 2004.(24) |
|-------|----------------------------------------------------------------------------------------------------------------------------|

| 10.15 | Novation Agreement dated April 11, 2008 relating to the Employment Agreement of Angus Russell dated March 10, 2004, as previously novated on November 21, 2005.(25) |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.16 | Form of Amended and Restated Employment Agreement between Shire plc and Mr Matthew Emmens, dated March 12, 2004.(26) |
|-------|----------------------------------------------------------------------------------------------------------------------|

| 10.17 | Amendment Agreement dated November 21, 2005 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004.(27) |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.18 | Ratification and Guaranty dated November 21, 2005 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004.(28) |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.19 | Amendment Agreement dated May 20, 2008 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004, as amended on November 21, 2005.(29) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.20 | Ratification and Guaranty dated May 20, 2008 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004.(30) |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.21 | Form of Indemnity Agreement for Directors of Shire Limited.(31) |
|-------|-----------------------------------------------------------------|

| 10.22 | Service Agreement between Shire Limited and Mr Angus Russell, dated July 2, 2008.(32) |
|-------|---------------------------------------------------------------------------------------|

| 10.23 | Service Agreement between Shire Limited and Mr Graham Hetherington, dated July 2, 2008.(33) |
|-------|---------------------------------------------------------------------------------------------|

| 10.24 | Form of Settlement Agreement and Mutual Release in re: Transkaryotic Therapies, Inc., by and between Shire Human Genetic Therapies, Inc., Shire plc and the parties set forth therein. (34) |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.25 | Amended Agreement dated February 24, 2009 relating to the Product Development and License Agreement dated August 14, 2006.(35) |
|-------|--------------------------------------------------------------------------------------------------------------------------------|

| 10.26 | Amendment of the Service Agreement of A.C Russell dated January 15, 2010.(36) |
|-------|-------------------------------------------------------------------------------|

| 10.27 | Amendment to the Shire Portfolio Share Plan as approved by the Annual General meeting held on April 27, 2010.(37) |
|-------|-------------------------------------------------------------------------------------------------------------------|

| 10.28 | Multicurrency revolving and swingline facilities agreement as at November 23, 2010 by and among Shire plc & with a number of financial institutions, for which Abbey National Treasury Services Plc (trading as Santander Global Banking and Markets), Bank of America Securities Limited, Barclays Capital, Citigroup Global Markets Limited, Lloyds TSB Bank plc and The Royal Bank of Scotland plc acted as mandated lead arrangers and bookrunners and Credit Suisse AG, London Branch, Deutsche Bank AG, London Branch, Goldman Sachs International, Morgan Stanley Bank, N.A. and Sumitomo Mitsui Banking Corporation, Brussels Branch acted as arrangers. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 21 | List of Subsidiaries. |
|----|-----------------------|

| 31.1 | Certification of Angus Russell pursuant to Rule 13a – 14 under The Exchange Act. |
|------|----------------------------------------------------------------------------------------|

| 31.2 | Certification of Graham Hetherington pursuant to Rule 13a – 14 under The Exchange Act. |
|------|----------------------------------------------------------------------------------------------|

| 32.1 | Certification of Angus Russell and Graham Hetherington pursuant to Section 906 of the Sarbanes – Oxley Act of 2002. |
|------|---------------------------------------------------------------------------------------------------------------------------|

| (1) | Incorporated by reference to Exhibit 99.02 to Shire’s Form 8-K filed on April 25, 2005. |
|-----|-----------------------------------------------------------------------------------------------|

----

| (2) | Incorporated by reference to Exhibit 2.1 to Shire’s Form 8-K filed on February 23, 2007. |
|-----|------------------------------------------------------------------------------------------------|

| (3)   | Incorporated by reference to Exhibit 2.1 to Shire’s Form 8-K filed on July 10, 2008. |
|-----------------|--------------------------------------------------------------------------------------------|

| (4)  | Incorporated by reference to Exhibit 99.02 to Shire’s Form 8-K filed on October 1, 2008. |
|-----------|------------------------------------------------------------------------------------------------|

| (5) | Incorporated by reference to Exhibit 3.1 to Shire’s Form 8-K filed on April 29, 2011. |
|-----|---------------------------------------------------------------------------------------------|

| (6) | Incorporated by reference to Exhibit 4.01 to Shire’s Form 8-K filed on May 23, 2008. |
|-----|--------------------------------------------------------------------------------------------|

| (7)   | Incorporated by reference to Exhibit 4.02 to Shire’s Form 8-K filed on May 23, 2008. |
|-----------------|--------------------------------------------------------------------------------------------|

| (8) | Incorporated by reference to Exhibit 4.03 to Shire’s Form 8-K filed on May 23, 2008. |
|-----|--------------------------------------------------------------------------------------------|

| (9)  | Incorporated by reference to Exhibit 4.04 to Shire’s Form 8-K filed on May 23, 2008. |
|-----------|--------------------------------------------------------------------------------------------|

| (10) | Incorporated by reference to Exhibit 4.05 to Shire’s Form 10-K filed on February 27, 2009. |
|------|--------------------------------------------------------------------------------------------------|

| (11) | Incorporated by reference to Exhibit 99.1 to Shire’s Form 8-K filed on February 23, 2007. |
|------|-------------------------------------------------------------------------------------------------|

| (12) | Incorporated by reference to Exhibit 10.2 to Shire’s Form 10-Q filed on May 1, 2007. |
|------|--------------------------------------------------------------------------------------------|

| (13) | Incorporated by reference to Exhibit 10.01 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (14) | Incorporated by reference to Exhibit 10.1 to Shire’s Form 10-Q filed on August 2, 2007. |
|------|-----------------------------------------------------------------------------------------------|

| (15) | Incorporated by reference to Exhibit 10.2 to Shire’s Form 10-Q filed on August 2, 2007. |
|------|-----------------------------------------------------------------------------------------------|

| (16) | Incorporated by reference to Exhibit 10.3 to Shire’s Form 10-Q filed on August 2, 2007. |
|------|-----------------------------------------------------------------------------------------------|

| (17) | Incorporated by reference to Exhibit 10.02 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (18) | Incorporated by reference to Exhibit 10.03 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (19) | Incorporated by reference to Exhibit 10.09 to Shire’s Form 10-K/A filed on May 30, 2008. |
|------|------------------------------------------------------------------------------------------------|

| (20) | Incorporated by reference to Exhibit 10.1 to Shire’s Form 10-Q filed on November 7, 2006. |
|------|-------------------------------------------------------------------------------------------------|

| (21) | Incorporated by reference to Exhibit 10.2 to Shire’s Form 10-Q filed on November 7, 2006. |
|------|-------------------------------------------------------------------------------------------------|

| (22) | Incorporated by reference to Exhibit 10.3 to Shire’s Form 10-Q filed on November 7, 2006. |
|------|-------------------------------------------------------------------------------------------------|

| (23) | Incorporated by reference to Exhibit 10.11 to Shire’s Form 10-K filed on March 12, 2004. |
|------|------------------------------------------------------------------------------------------------|

| (24) | Incorporated by reference to Exhibit 10.03 to Shire’s Form 8-K filed on November 25, 2005. |
|------|--------------------------------------------------------------------------------------------------|

| (25) | Incorporated by reference to Exhibit 10.06 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (26) | Incorporated by reference to Exhibit 10.13 to Shire’s Form 10-K filed on March 12, 2004. |
|------|------------------------------------------------------------------------------------------------|

| (27) | Incorporated by reference to Exhibit 10.01 to Shire’s Form 8-K filed on November 25, 2005. |
|------|--------------------------------------------------------------------------------------------------|

| (28) | Incorporated by reference to Exhibit 10.02 to Shire’s Form 8-K filed on November 25, 2005. |
|------|--------------------------------------------------------------------------------------------------|

| (29) | Incorporated by reference to Exhibit 10.04 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (30) | Incorporated by reference to Exhibit 10.05 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (31) | Incorporated by reference to Exhibit 10.07 to Shire’s Form 8-K filed on May 23, 2008. |
|------|---------------------------------------------------------------------------------------------|

| (32) | Incorporated by reference to Exhibit 10.22 to Shire’s Form 10-Q filed on November 10, 2008. |
|------|---------------------------------------------------------------------------------------------------|

| (33) | Incorporated by reference to Exhibit 10.23 to Shire’s Form 10-Q filed on November 10, 2008. |
|------|---------------------------------------------------------------------------------------------------|

| (34) | Incorporated by reference to Exhibit 10.24 to Shire’s Form 10-Q filed on November 10, 2008. |
|------|---------------------------------------------------------------------------------------------------|

| (35) | Incorporated by reference to Exhibit 10.25 to Shire’s Form 10-Q filed on May 7, 2009. |
|------|---------------------------------------------------------------------------------------------|

| (36) | Incorporated by reference to Exhibit 10.26 to Shire’s Form 10-K filed on February 26, 2010. |
|------|---------------------------------------------------------------------------------------------------|

| (37) | Incorporated by reference to Exhibit 10.27 to Shire's Form 10-Q filed on May 6, 2010. |
|------|---------------------------------------------------------------------------------------|

----

| Date:    May 6, 2011 | /s/ Angus RussellAngus RussellChief Executive Officer              |
|-------------------------------------|-------------------------------------------------------------------------|
|                                |                                                                    |
|                                |                                                                    |
| Date:    May 6, 2011 | /s/ Graham HetheringtonGraham HetheringtonChief Financial Officer  |
|                                |                                                                    |
|                                |                                                                    |

----